French Rhenovia leads project to evaluate the effects of neurotoxins to military personnel
Mulhouse - French systems biology specialist Rhenovia Pharma SAS has been selected to lead a EUR 1.15 million research programme in partnership with the French Army's Biomedical Research Institute (IRBA). Within the RHETOX programme, the company will receive EUR850,000 for developing a platform technology aimed at modelling the neurobiological effects of exposure to battlefield neurotoxic agents in order to develop more effective medical counter-measures. Rhenovia will incorporate in ist biosimulation platform the molecular elements required to analyze the effects of organophosphoric neurotoxic agents, such as sarin and soman, as well as pesticides/insecticides like paraoxon, which have similar chemical characteristics and pharmacological properties. According to the firm, the RHETOX neurotoxicity biosimulation platform will also have pharmaceutical applications. For example, it should make it possible to predict the secondary neurotoxic effects of any type of drug or NCE on different neuronal molecular targets, opening up early identification of safety problems with new drug candidates. The company's biosimulation platform aims at developing mathematical modelling and computer simulation tools to systematically explore the contribution of various molecular processes in glutamatergic synaptic transmission, and the effects of those synaptic processes on multi-synaptic cellular dynamics, and ultimately, on the behaviour of a small network of hippocampal neurons.